Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions
Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity
Interventions
DRUG

Methotrexate

Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Clinica de la Costa, Barranquilla

All Listed Sponsors
lead

George Washington University

OTHER